Drug Patents owned by Medicure

1. Drug name - AGGRASTAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6770660 MEDICURE Method for inhibiting platelet aggregation May, 2023

(6 months from now)

Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs

Dosage: INJECTABLE;INJECTION; SOLUTION;INJECTION

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML) INJECTABLE;INJECTION Discontinued
EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) SOLUTION;INJECTION Prescription

2. Drug name - ZYPITAMAG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8829186 MEDICURE Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof
Jan, 2031

(8 years from now)

IN310062B MEDICURE Method For Preparation Of Pitavastatin And Its Pharmaceutical Acceptable Salts Thereof
Jan, 2030

(7 years from now)

IN201000159I3 MEDICURE Method For Preparation Of Pitavastatin And Its Pharmaceutical Acceptable Salts Thereof
Jan, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET;ORAL Discontinued
EQ 2MG BASE TABLET;ORAL Prescription
EQ 4MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.